MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which Reneo shareholders will only own approximately 31% of the combined company.
If you remain a Reneo shareholder and have concerns about the transaction, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/reneo-pharmaceuticals/
Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com.
Why is there an investigation?
On May 13, 2024, Reneo announced that it had agreed to merge with OnKure in a stock-for-stock transaction under which Reneo shareholders will only own approximately 31% of the combined company.
“We are investigating whether the Reneo Board of Directors acted in the best interests of Reneo shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the percentage of the combined company allocated to Reneo shareholders is fair, and whether all material information regarding the transaction has been fully disclosed.”
About Wohl & Fruchter
Wohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
alerts@wohlfruchter.com
www.wohlfruchter.com
